Abstract
Chronic studies were initiated in rats to determine the effects of high- and low-dose tranylcypromine (TCP) on [3H]tryptamine (3H-T) binding sites. Male Sprague-Dawley rats were administered TCP (0.5 or 2.5 mg/kg/day) or vehicle (distilled water) for 4, 10 or 28 days via Alzet minipumps. After decapitation, the hippocampus and striatum were used to prepare membrane fragments for single point3H-T binding. Hippocampal3H-T binding was reduced after 10 and 28 days with the low dose and after 4, 10 and 28 days with the high dose. Striatal3H-T binding was reduced by both doses at all time intervals. The high dose resulted in a significantly greater reduction in striatal3H-T binding than did the low-dose after 4, 10, and 28 days. These results suggest that a more rapid reduction of3H-T binding in the hippocampus and/or a greater reduction of3H-T binding in the striatum by high-dose TCP than by low-dose TCP may be contributing factors in the reported efficacy of the former in refractory depression.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Robinson D. S. 1983. High-dose monoamine oxidase-inhibitor therapy. j. Am. Med. Assoc. 250:2212.
Guze B. H., and Baxter L. R. Jr. 1987. Refractory depression treated with high doses of monoamine oxidase inhibitor. J Clin Psychiat 48:31–32.
Pearlman C. 1987. High dose tranylcypromine in refractory depression. J Clin Psychiat 48:424.
Amsterdam J. D., and Berwish N. J. 1989. High dose tranylcypromine treatment for refractory repression. Pharmacopsychiat 22:21–25.
Ferris R. M., Howard J. L., and White H. L. 1975. A relationship between clinical efficacy and various biochemical parameters of monoamine oxidase inhibitors (MAOIs), Pharmacologist 17:451.
Robinson, D. S., Nies A., Ravaris C. L., Ives J. O., and Barlett D. 1978. Clinical pharmacology of phenelzine: MAO activity and clinical response. Pages 961–974, in Lipton M., Dimascio A. and Killam K. F. (eds.), Psychopharmacology: A Generation of Progress, Raven Press, New York.
Giller E. G. and Leib, J. 1980. Monoamine oxidase inhibitors and platelet monoamine oxidase inhibition, Comm Psychopharmacol 4:79–82.
Giller E. G., Bialos, D., Riddle, M., Sholomskas, A., and Harkness. L. 1982. Monoamine oxidase inhibitor-responsive depression, Psychiat Res 6:41–48.
Philips S. R., Durden D. A., and Boulton A. A. 1974. Identification and distribution of tryptamine in the rat, Can J Biochem 52:447–451.
Philips S. R., and Boulton A. A. 1979. The effect of monoamine oxidase inhibitors on some arylalkylamines in rat striatum. J Neurochem 33:159–167.
Philips S. R., Baker G. B., and McKim H. R. 1980. Effects of tranylcypromine on the concentrations of some trace amines in the diencephalon and hippocampus of the rat, Experientia 36:241–242.
Baker G. B., LeGatt D. F., and Coutts R. T. 1984. A comparison of the effects of acute and chronic administration of phenelzine and tranylcypromine on brain concentrations of 2-phenylethylamine,p-tyramine and tryptamine in the rat. Pages 277–282,in Boulton A.A., Baker G. B., Dewhurst W. G. and Sandler M. (eds.), Neurobiology of the Trace Amines, Humana Press, Clifton, N.J.
Dewhurst W. G. 1968. New theory of cerebral amine function and its clinical application, Nature (Lond) 218:1130–1133.
Bieck P. R., Nilsson E., Schick C., Waldmeier P. C., and Lauber J. 1984. Urinary excretion of tryptamine in comparison to normetanephrine and β-phenylethylamine in human volunteers after subchronic treatment with different monoamine oxidase inhibitors. Pages 525–539,in Boulton A. A., Baker G. B., Dewhurst W. G. and Sandler M. (eds.), Neurobiology of the Trace Amines, Humana Press, Clifton, N.J.
Baker G. B., Coutts R. T., Yeung J. M., Hampson D. R., McIntosh G. J. A., and McIntosh M. 1985. Chronic administration of monoamine oxidase inhibitors: basic and clinical investigations. Pages 317–328,in Boulton A. A., Maitre L., Bieck P. R., and Riederer P. (eds.), Neuropsychopharmacology of the Trace Amines: Experimental and Clinical Aspects, Humana Press, Clifton, N.J.
McKenna K. F., Baker G. B., and Coutts R. T. 1993. Urinary excretion of bioactive amines and their metabolites in psychiatric patients receiving phenelzine, Neurochem Res (in press).
Baker G. B., Martin I. L., and Mitchell P. R. 1977. The effects of some indolalkylamines on the uptake and release of 5-hydroxytryptamine in rat striatum, Br J Pharmacol 61:151P-152P.
Jones R. S. G., and Boulton A. A. 1981. Tryptamine and 5-hydroxytryptamine's actions and interactions on cortical neurones in the rat. Life Sci 27:1849–1856.
Greenshaw A. J., and Dewhurst W. G. 1987. Tryptamine receptors: Fact, myth or misunderstanding? Brain Res Bull 18:253–256.
Graham D., and Langer S. Z. 1987.3H-Tryptamine binding sites of rat cerebral cortex: pharmacological profile and plasticity, Neuropharmacol 26:1093–1097.
van Nguyen T. V., Paterson I. V., Juorio A. V., Greenshaw A. J. and Boulton A. A. 1989. Tryptamine receptors: neurochemical and electrophysiological evidence for postsynaptic and functional binding sites. Brain Res 476:85–93.
Osborne N. N., and Hogben M. 1988. The effects of various indoles on the stimulation of inositol phosphate formation in rat cortical slices. Pages 251–260,in Boulton A. A., Juorio A. V., and Downer R. G. H. (eds.), Trace Amines: Comparative and Clinical Neurobiology, Humana Press, Clifton, N.J.
Kellar K. J., and Cascio C. S. 1986. Tryptamine and phenethylamine recognition sites in brain. Pages 119–137,in Boulton A. A., Baker G. B. and Hrdina P. D. (eds.), Neuromethods, Vol. 4: Receptor Binding, Humana Press, Clifton, N.J.
Martin L. L., Neale R. F., and Wood P. L. 1987. Down-regulation of tryptamine receptors following chronic administration of clorgyline, Brain Res 419:239–243.
van Nguyen T. V., and Juorio A. V. 1989. Down-regulation of tryptamine binding sites following chronic molindone administration, Naunyn-Schmied Arch Pharmacol 340:366–371.
Mousseau D. D., McManus D. J., Baker G. B., Juorio A. V., Dewhurst W. G., and Greenshaw A. J. 1993. Effects of age and of chronic antidepressant treatment on3H-tryptamine binding to rat cortical membranes, Cell Mol Neurobiol 13:3–13.
Sherry-McKenna R. L., Baker G. B., Mousseau D. D., Coutts R. T., and Dewhurst W. G. 1992. 4-Méthoxytranylcypromine, a monoamine oxidase inhibitor: effects on biogenic amines in rat brain following chronic administration, Biol Psychiat 31:881–888.
Cascio C. S., and Kellar K. J. 1983. Characterization of3H-tryptamine binding sites in brain. Eur J Pharmacol 95:31–39.
Wood P. L., Pilapil C., LaFaille F., Nair N. P. V., and Glennon R. A. 1984. Unique3H-tryptamine binding sites in rat brain: Distribution and pharmacology. Arch Int Pharmacodyn 268:194–201.
Wurtman R. J., and Axelrod J. 1963. A sensitive and specific assay for the estimation of monoamine oxidase, Biochem Pharmacol 12:1439–1441.
Lowry O. H., Rosenbrough N. J., Farr A. L., and Randall R. J. 1951. Protein measurements with the Folin phenol reagent. J Biol Chem 193:265–275.
Baker G. B., Coutts R. T., McKenna K. F., and Sherry-McKenna R. L. 1992. Insights into the mechanisms of action of the MAO inhibitors phenelizine and tranylcypromine: a review. J. Psychiatr. Neurosci. 17:206–214.
Juorio A. V., and Paterson I. A. 1990. Tryptamine may couple doopaminergic and serotoninergic transmission in the brain, Gen. Pharmacol. 5:613–616.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Goodnough, D.B., Baker, G.B., Mousseau, D.D. et al. Effects of low- and high-dose tranylcypromine on [3H]tryptamine binding sites in the rat hippocampus and striatum. Neurochem Res 19, 5–8 (1994). https://doi.org/10.1007/BF00966720
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00966720